Alnylam Pharmaceuticals, Inc. (ALNY) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alnylam Pharmaceuticals, Inc. (ALNY)

ALNY 456.04

+1.4%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tuck	3/28/2008 11:53:01 AM
	Read Replies (1) of 166

Cross posting from RNAi thread interesting new work that finds darn near any siRNA can modulate angiogenesis. The real target appears to be TLR3, a cell surface receptor whose down stream affects on various cytokines, etc. can -- among other things -- modulate angiogenesis. Bad news in a couple of ways: 1) what will the FDA think of this?, and 2) what are the implications for competition and IP? Message 24447956 This might explain recent weakness in RNAi companies. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next